IBA Proteus TK2 krijgt oplossingen voor patiëntbeheer van Elekta
Array
Elekta, ontwikkelaar van baanbrekende medische vernieuwingen en klinische oplossingen voor de behandeling van kanker en hersenaandoeningen, gaat instrumenten voor workflow- en patientbeheer bij de behandeling van kanker integreren in de Proteus TK2, een bedrijfsklaar protontherapiecentrum van het Belgische bedrijf Ion Beam Applications (IBA).
Het IBA protontherapiesysteem bestaat onder meer uit een cyclotron, een gantry en een behandelkamer met vaste stralenbundel. IBA en Elekta maakten hun samenwerking bekend op het Jubileumcongres van de Europese Vereniging voor Therapeutische Radiologie en Oncologie (ESTRO), 8-12 mei 2011 in Londen, en de conferentie van de Particle Therapy Co-Operative Group (PTCOG), 8-14 mei 2011 in Philadelphia.
Engelstalig bericht:
Details highlighted at the 50th meeting of PTCOG, Philadelphia, Penn., USA and The 11th Biennial ESTRO Conference, London, UK
Elekta, a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders, will integrate cancer workflow and patient management tools into the Proteus TK2â„¢, a turnkey proton therapy center from Belgium-based Ion Beam Applications (IBA). The IBA proton therapy system includes a cyclotron, beam line, gantry treatment room and a fixed-beam treatment room.
IBA and Elekta announced their collaboration at the European Society of Therapeutic Radiology and Oncology (ESTRO) Anniversary Congress in London, UK, 8-12 May 2011, and the Particle Therapy Co-Operative Group (PTCOG) conference in Philadelphia, Penn., USA, 8-14 May 2011.
“IBA’s Proteus TK2 is a ‘no worries’ approach for a cancer center’s executive to successfully build a proton therapy department for their patients,†says Pierre Mottet, Chief Executive Officer of IBA. “It covers everything from project planning to financing, construction, proton system installation and day-to-day operations and service. Incorporating Elekta’s integrated patient management tools provides a consistently reliable diagnostic and treatment system in which clinicians and patients can completely trust.â€
Elekta software and devices included in the Proteus TK2 center are the MOSAIQ® oncology information system designed specifically for oncology settings, including proton therapy clinics; auto-segmentation solutions, comprehensive treatment planning functionality that supports conventional radiation and proton-beam therapies — including uniform scanning, scattering and spot scanning with Intensity Modulated Proton Therapy; non-invasive patient immobilization and positioning systems that provide accurate and reproducible positioning for proton therapy; and respiratory motion management to help reduce treatment margins.
“Elekta’s world leading patient management solutions, which deliver oncology optimized workflow solutions will enhance the patient experience, reduce clinical risk and maximize return on investment,†says Stewart Pegrum, Director Particle Therapy, Elekta. “And, clinicians know Elekta will refine its software and hardware with every advance in proton therapy technology and treatment.â€
ABOUT ELEKTA
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow-enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that give confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.
Today, Elekta solutions in oncology and neurosurgery are used in more than 5,000Â hospitals globally, and every day more than 100,000Â patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.
Elekta employs about 2,500Â employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb.
Website: www.elekta.com
ABOUT IBA
IBA develops and markets leading-edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
Website: www.iba-worldwide.com
